mannonDr. Mannon joined UAB in 2008 as a Professor of Medicine. He received both his bachelor’s and medical degrees from Boston University, and completed fellowship training in Gastroenterology from Johns Hopkins University.  Dr. Mannon also completed an extensive research fellowhip at Duke University focusing in gastrointestinal disorders.  Prior to joining UAB, Dr. Mannon served as Assistant Professor at Duke University as well as Professor at the Uniformed Services University of Health Sciences in Bethesda, Maryland.  Dr. Mannon’s current clinical practice includes the treatment of gastrointestinal disorders, and his research focus is on the development of new treatment options for Inflammatory Bowel Disease.

Recent Publications

1.     Suppression of inflammation in ulcerative colitis by interferon-{beta}-1a is accompanied by inhibition of IL-13 production. Mannon PJ, Hornung RL, Yang Z, Yi C, Groden C, Friend J, Yao M, Strober W, Fuss IJ. Gut. 2010 Oct 22

2.     Gut permeability and colitis. Mannon P. Gastroenterology. 2009 Aug;137(2):732-4

3.     A common barrier defect for celiac disease and ulcerative colitis. Mannon PJ. Gastroenterology. 2008 Dec;135(6):2145-7

4.     GAIN for loss: adalimumab for infliximab-refractory Crohn disease. Mannon P. Ann Intern Med. 2007 Jun 19;146(12):888-90

5.     Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Mannon PJ, Fuss IJ, Dill S, Friend J, Groden C, Hornung R, Yang Z, Yi C, Quezado M, Brown M, Strober W. Gastroenterology. 2006 Sep;131(3):748-56

6.     Anti-interleukin-12 antibody for active Crohn’s disease. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W; Anti-IL-12 Crohn’s Disease Study Group. N Engl J Med. 2004 Nov 11;351(20):2069-79. Erratum in: N Engl J Med. 2005 Mar 24;352(12):1276